Cell Therapy News

American Society for Transplantation and Cellular Therapy presented awards to three leaders in the fields.

Black patients appeared consistently underrepresented in pivotal clinical trials that led to FDA approval of several chimeric antigen receptor T-cell therapies, according to findings published in JAMA Network Open.

THOROFARE, NJ — Healio is set to host the inaugural hematology/oncology Disruptive Innovators Award Reception during the American Society of Clinical Oncology Annual Meeting. The event will take place on June 4, 2022, at the Hyatt Regency McCormick Place in Chicago, Illinois.

Younger patients who developed treatment-related hemophagocytic lymphohistiocytosis after tisagenlecleucel infusion for relapsed or refractory B-cell acute lymphoblastic leukemia had significantly poorer outcomes, according to study results.

Over the last decade, “telehealth” became a buzzword in conversations about health care innovation.

Tisagenlecleucel may be less toxic than axicabtagene ciloleucel for patients with relapsed or refractory follicular lymphoma, study results suggested.

The FDA has halted a clinical trial for an investigational stem cell-derived therapy for people with type 1 diabetes, according to an industry press release.

Despite a high upfront price, treatment with axicabtagene ciloleucel appeared more cost-effective as second-line therapy than standard treatment for relapsed or refractory large B-cell lymphoma, according to study results.

The FDA granted regenerative medicine advanced therapy designation to obecabatagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

The addition of utomilumab after infusion with axicabtagene ciloleucel induced a 75% response rate among adults with relapsed or refractory large B-cell lymphoma, data from the ZUMA-11 trial showed.